List of Biotech, Pharmaceutical & Life Sciences companies in Alabama - 33

Alabama Agricultural and Mechanical University(AAMU) is a historic, student-friendly and community-focused institution of higher learning. Reflecting on its heritage as a historical black college and university (HBCU) and a traditional 1890 land-grant institution, AAMU functions as a teaching, research and public service institution, including extension.

Specialize in molecular and toxicology assays and technology.COVID-19: Molecular test, EUA (05/2020)

Auburn University is a higher education institution that offers a wide range of academic programs and conducts research in various fields.

As a primary turkey breeder, we are aware of our responsibility to both our customers and the environment. Investment and innovation are key to breed development, producing premium-quality turkeys of the future. Sustainability: Aviagen Turkeys is committed to developing breeds and adopting internal production practices that not only support cost-effective food production, but also supports social responsibility and environmental sustainability. Aviagen Turkeys is proud to be a leader in both new technologies and environmental stewardship. We will continue to supply the world with a valuable protein source while minimizing environmental impact and emphasizing conservation. Customer Support: Aviagen Turkeys provides support to ensure customers can maximize the genetic potential, efficiency and profitability within their systems. As well as attending many of the global poultry exhibitions to meet customers face to face, Aviagen Turkeys have previously held open days to help guide and support customers within the industry. Aviagen Turkeys provides an exceptional resource of information and expertise to customers, comprising of knowledge and experience gained from productions around the world to maximise the performance of the B.U.T and Nicholas breeds.

BioGX develops molecular products and provides partner-specified formulation and manufacturing services for molecular reagents on a platform of a partner’s choice. The company applies its proprietary platform-agnostic reagent technology to offer products and contract services across a variety of real-time PCR and Next Generation Sequencing platforms.BioGX SARS-CoV-2 Reagents for the BD MAX System - EUA 4/2020

Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics'​ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory. For more information, visit www.bridgetherapeutics.com.

CFD Research Corporation (CFDRC) specializes in engineering simulations and innovative designs for Aerospace, Biomedical, Defense, Materials, Energy, and other industries. Using our software and experimental facilities, we develop new hardware concepts, innovative designs, and prototypes. We have over 50 patents awarded or pending in the areas of biotechnology, combustion, propulsion, and materials. CFDRC’s software and expertise allow coupled multiscale, multiphysics simulations of fluid, thermal, chemical, biological, electrical, and mechanical phenomena for real-world applications. Such simulations provide dearer insights into complex systems and thus enable better decisions and facility better products with lower risk, reduced cost, and less time.

Concero Scientific's mission is safeguarding the Warfighter and the Homeland from biothreats by accelerating prevention, response and control solutions for infectious diseases and bioagents through research, development and integration of cutting-edge life science discoveries.

Curiteva is a privately held technology and manufacturing company dedicated to advancing spine surgery and improving clinical outcomes by partnering with providers and suppliers to deliver innovative and intuitive implant systems to the market. Our business is founded on a commitment to building world-class manufacturing, accelerating research and development, maintaining lean operational discipline, and delivering novel technology to meet the evolving needs of our customers and the patients they serve.

A unique laboratory providing accurate and actionable results in one day for infectious diseases and antibiotic resistance genes utilizing innovative molecular technologies, including proprietary TEM-PCR™. Eurofins Diatherix distinctions: - Delivers one-day results - Identifies bacteria regardless of recent antibiotic use - Offers simplicity of single-sample collection - Identifies difficult-to-culture pathogens - Yields a high level of sensitivity and specificity

In many medical settings, devices are commonly used to help doctors treat patients. For example, stents are often used to open blocked arteries, repair torn vessels, and even to keep nasal passages from swelling shut after surgery. Unfortunately these devices fail often resulting in additional surgeries and often replacements of the original device. Endomimetics has developed a BioNanomatrix that can be used to coat these devices and mimic human tissue which minimizes the need for additional surgeries, improves the longevity of the device, reduces complications associated with having foreign items implanted in your body. Applications Our endothelium mimicking nitric oxide releasing BioNanomatrix, initially developed for coronary and peripheral stents, is being assessed for several novel applications including: Stents to help with heart disease Stents and blood flow diverters to help with brain aneurysms Fistula implantation for dialysis patients Intranasal implants for chronic sinusitis sufferers

Detecting Pathogens Takes Too Long Our patented CAPTURE (Confirm Active Pathogens Through Unamplified RNA Expression) technology solves this problem, and we are now developing a portable instrument to screen for hundreds of pathogens within an hour for less than $20. GeneCapture's unique approach to disease diagnostics uses rapid RNA-based technology to bring infection detection to the Point of Care; whether that's a hospital bed, an airport, a cruise ship, or a battlefield.

HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. Opened in 2008, HudsonAlpha's vision is to leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation's second largest research park. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and fosters more than 45 diverse biotech companies on campus.

Rapid Syndromic Testing for All Labs The mission of iCubate® is to provide rapid, accurate and affordable syndromic testing to all laboratories to ensure care providers have the right tools to improve care and outcomes for their patients. The iCubate® team has developed the iC System™, a low-cost, fully automated, molecular diagnostic platform using armPCR technology, along with a suite of syndromic infectious diseases panels, including sepsis/positive blood cultures, upper / lower respiratory tract infections, GI, mycobacteria, and more. Why iCubate for your lab? • Rapid syndromic testing for infectious diseases for better care, sooner • Affordable system increasing accessibility for large and small labs • Multiplex assay with high target specificity and sensitivity for actionable results • 3 minutes of hands-on time with routine lab processes Twitter: @iCubate FDA Cleared Products iC-System™ (iCubate’s platform) iC-GPC Assay™ for Gram positive cocci Anticipated clearance 2019 iC-GN Assay™ for Gram negative rods Robust Assay Pipeline GI, Respiratory, Mycobacterium

Immunowake focuses on identifying new therapies for patients who do not respond to existing treatments. Our strategy involves harnessing the body’s immune system to identify and kill cancer cells the same way pathogens are identified and targeted. Recent breakthroughs in cancer immunotherapy have demonstrated that powerful anti-tumor responses can be achieved by activating antigen specific T-cells.

iRepertoire was the first to develop and commercialize immune repertoire sequencing technology and products. iRepertoire uses immune repertoire sequencing technology to access the body’s immunological memory, or “logbook” of all past infection and disease. Sequencing the immune repertoire can yield insights into the nature of the body’s immune response to disease and infection. The future market for iRepertoire will be in clinical and research applications that require immune assessment such as drug treatment monitoring, identification of minimal residual disease (MRD), immune monitoring after stem cell transplantation, vaccine studies, and biomarker development.  iRepertoire provides primer kits and amplification to sequencing services to examine the TCR and BCR immune diversity in both humans and mice. iRepertoire also offers access to its proprietary repertoire analysis tools with the purchase of its regent systems.  iRepertoire’s reagent systems allow researchers to easily and inexpensively generate their own Next Generation Sequencing libraries in the convenience of their laboratory and analyze their data with the iRepertoire’s proprietary software pipeline at no additional cost.This year, iRepertoire has launched automated immune repertoire amplification and extraction on their sister company’s iC-processor (iCubate, Inc.). iRepertoire is proud to be a part of the non-profit initiative R10K, or Repertoire 10,000, with the HudsonAlpha Institute for Biotechnology, which aims to study the immune repertoire of 100 different diseases. The company has developed two key indices to describe the immune repertoire, i.e., the diversity index and the sharing index. These indices allow iRepertoire to identify disease specific signatures for diagnosis, prognosis, and treatment guidance.

iXpressGenes is a synthetic biology company thatspecializes in protein services and instrumentation, and protein and genetic engineering research. The company has experience withextremozymes, microgravity, and trace fluorescent labeling andaccess to a suite of hyperthermophilic genomes from the deep sea vents of the Atlantic Ridge. Proteins and enzymes from these genomes have special qualities that are useful in engineering and metabolic reactions.

Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to your lifestyle.

Founded in 2024, Kalm Therapeutics is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of patients with mild to moderate atopic dermatitis and psoriasis. We offer a steroid-free, natural alternative to the growing number of adults and children battling eczema.

LifeActive Bio is a pre-clinical biomaterials company with the mission to extend the quality of human life by transforming molecular delivery and improving how therapeutic compounds are absorbed by the human body. LifeActive Bio has developed a Molecular Administration Platform™, a novel, proprietary, patent-pending platform technology that encapsulates molecules with absorption directly through the skin into the body. LifeActive Bio has successfully conducted preclinical studies to evaluate safety, tolerability and bioavailability using Molecular Administration Platform™ technology. LifeActive Bio's global research center is based at MBC BioLabs in San Carlos, Calif., a multi-disciplinary life sciences R&D lab focused on developing breakthrough medical innovations. For more information about LifeActive Bio, visit www.lifeactivebio.com. For questions, please contact info@lifeactivebio.com

Microarrays is a biotechnology company that offers array products for biological research, detection, and diagnostics, focusing on advancing array-based technologies.

NuTech Spine was incorporated in 1994 by Founder and President, Ken Horton. Since then, NuTech has been on the cutting edge of Orthopedic, Spinal, and Sports Medicine. NuTech Spine offers quality products & services to its patients and physicians with knowledgeable staff and product literature.

science backed probiotics, prebiotics & bioactive botanicals for targeted restoration res makes physician developed & physician recommended supplements creator of the world's first respiratory probiotic resB!

Welcome and thank you for visiting the Rheumatology Associates of North Alabama. Our dedicated physicians, professional and friendly managers and staff mak

Score Pharma is developing new, more potent antibody therapeutics by transforming existing clinically proven antibody therapeutics for an improved patient response. Our team is prioritizing cancer therapies such as non-Hodgkin lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), and HER2-positive breast cancer. By enhancing existing technologies with a patent-pending improvement process, we expect better therapies with a higher probability of clinical and regulatory success.

Serina Therapeutics is a privately held biotechnology company located in Huntsville, Alabama. We have developed a proprietary, clinically-validated polymer technology based on the water-soluble polymer poly(oxazoline). We call it POZ for short. Please visit our website at www.serinatherapeutics.com and review the exciting work we are doing in vaccines, Parkinson's disease, pain, oncology and cannabinoid science.

Founded in 1982 to provide researchers with tools that were not readily available from other commercial sources, SouthernBiotech has remained a steadfast, high-quality source of secondary antibodies for research use. Over the years we have expanded our product line to meet researchers’ changing needs. What has not changed is our commitment to customer success.

Southern Research is a nonprofit, translational scientific research organization with an 80-year legacy of moving science through drug discovery, drug development and environmental health. This legacy includes helping shape modern cancer treatment practices by developing seven FDA-approved cancer drugs and co-creating a COVID-19 vaccine currently in clinical trials. These innovations are made possible because of our greatest assets, our people that move science every day at every level of Southern Research.

TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients' own islet cell health.

TriAltus Bioscience is a biotechnology company located in Birmingham, Alabama, that specializes in protein purification and the production of genomic enzymes for the life sciences industry. Founded in 2017, the company utilizes its proprietary CLīM technology to provide high-quality protein products, emphasizing high purity, yield, and activity. The company offers advanced protein purification solutions and produces a variety of genomic enzymes, including CRISPR enzymes, which are known for their quality and affordability. TriAltus Bioscience serves as a reliable protein supplier for innovative biotech and diagnostic companies, contributing to essential workflows in these fields. With a commitment to excellence, TriAltus Bioscience has established itself as a trusted partner in the biotechnology sector.

The UAB is a young, public and groundbreaking university. A leader in international rankings and a benchmark in research. Barcelonian, Catalan and international. A transformative, supportive, diverse and egalitarian, sustainable and healthy, participative and cultural university. And a campus university where you can live unique experiences.

Van Heron Labs is a company that develops technologies to enhance the health of humans and the planet by utilizing the power of genetics, bioinformatics, and AI to unify nutrient substrates. The company's cell-based applications include cancer therapeutics and food and materials production.

Yuva Biosciences is an anti-aging company harnessing the cutting edge of mitochondrial science to develop cosmeceuticals as well as pharmaceuticals targeted at aging-related hair loss, wrinkled skin, and reduced energy. The company has secured a multimillion dollar seed round and has also entered into licensing agreements with other companies to research and develop new aesthetics products.